HH Biotechnology Holdings Company (HHBT) Stock Analysis & Winston Score
HH Biotechnology Holdings Company is a small company based in China that operates in real estate services, despite its biotechnology-sounding name. It provides property-related services, likely including agency, consulting, or management services, to buyers, sellers, or developers in the Chinese real estate market. The company is very small, with a market capitalization that rounds to essentially zero. The company earns revenue through fees charged for its real estate services, which explains its roughly 29% gross margin. It operates primarily in China, a market that has faced significant stress in recent years due to a prolonged property sector downturn affecting developers and transaction volumes. The deeply negative return on invested capital of -112.6% is a serious warning sign, suggesting the company is destroying value rather than creating it, and the main risk it faces is surviving in a weak Chinese property market while rebuilding profitability from a very fragile financial position.
Winston Score: 50/100 — Average
Mixed quality — meaningful strengths and weaknesses.
- Quality: Good (17/30)
- Growth: Data not available (0/20)
- Cash Flow: Exceptional (10/10)
- Stability: Strong (7/10)
- Valuation: Good (6/10)
- Ownership: Ownership data not available (not counted) (0/15)
Key Facts
Price: $0.00
Market Cap: $0M
Sector: Real Estate
Industry: Real Estate - Services

